RT Journal Article
SR Electronic
T1 Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.21.20248640
DO 10.1101/2020.12.21.20248640
A1 Houriiyah Tegally
A1 Eduan Wilkinson
A1 Marta Giovanetti
A1 Arash Iranzadeh
A1 Vagner Fonseca
A1 Jennifer Giandhari
A1 Deelan Doolabh
A1 Sureshnee Pillay
A1 Emmanuel James San
A1 Nokukhanya Msomi
A1 Koleka Mlisana
A1 Anne von Gottberg
A1 Sibongile Walaza
A1 Mushal Allam
A1 Arshad Ismail
A1 Thabo Mohale
A1 Allison J Glass
A1 Susan Engelbrecht
A1 Gert Van Zyl
A1 Wolfgang Preiser
A1 Francesco Petruccione
A1 Alex Sigal
A1 Diana Hardie
A1 Gert Marais
A1 Marvin Hsiao
A1 Stephen Korsman
A1 Mary-Ann Davies
A1 Lynn Tyers
A1 Innocent Mudau
A1 Denis York
A1 Caroline Maslo
A1 Dominique Goedhals
A1 Shareef Abrahams
A1 Oluwakemi Laguda-Akingba
A1 Arghavan Alisoltani-Dehkordi
A1 Adam Godzik
A1 Constantinos Kurt Wibmer
A1 Bryan Trevor Sewell
A1 José Lourenço
A1 Luiz Carlos Junior Alcantara
A1 Sergei L Kosakovsky Pond
A1 Steven Weaver
A1 Darren Martin
A1 Richard J Lessells
A1 Jinal N Bhiman
A1 Carolyn Williamson
A1 Tulio de Oliveira
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248640.abstract
AB Continued uncontrolled transmission of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in many parts of the world is creating the conditions for significant virus evolution. Here, we describe a new SARS-CoV-2 lineage (501Y.V2) characterised by eight lineage-defining mutations in the spike protein, including three at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance. This lineage emerged in South Africa after the first epidemic wave in a severely affected metropolitan area, Nelson Mandela Bay, located on the coast of the Eastern Cape Province. This lineage spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces. Whilst the full significance of the mutations is yet to be determined, the genomic data, showing the rapid displacement of other lineages, suggest that this lineage may be associated with increased transmissibility.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.krisp.org.za/ngs-sa/ Funding StatementThis research reported in this publication was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee. Protocol reference number: BREC/00001510/2020. Project title: Spatial and genomic monitoring of COVID-19 cases in South Africa. This project was also approved by University of the Witwatersrand Human Research Ethics Committee. Clearance certificate number: M180832. Project title: Surveillance for outpatient influenza-like illness and asymptomatic virus colonization in South Africa. Sequence data from the Western Cape was approved by the Stellenbosch University HREC Reference No: N20/04/008_COVID-19. Project Title: COVID-19: sequencing the virus from South African patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomic data has been deposited in GISAID